High dose vitamin D supplementation does not prevent CVD

Goodfellow Gems Logo

Goodfellow Gems

High dose vitamin D supplementation does not prevent CVD  

In this New Zealand randomized clinical trial of 5,108 community participants,1 the cumulative incidence of cardiovascular disease for a median follow-up period of 3.3 years was 11.8% among participants given vitamin D monthly and 11.5% among those given placebo. 

The dosage regime was oral vitamin D3 in an initial dose of 200 000 IU, (5 mg or 4 Cholecalciferol tablets in NZ) followed by monthly doses of 100 000 IU, (2 NZ tablets) or placebo for a median of 3.3 years. Those with a low serum level at baseline found similar results. 

Cohort studies have reported increased incidence of cardiovascular disease (CVD) among individuals with low vitamin D status.

To date, randomized clinical trials of vitamin D supplementation have not found an effect, possibly because of using too low a dose of vitamin D.

References:

  1. Scragg R et al. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study: A Randomized Clinical Trial. JAMA Cardiology. Published online April 5, 2017. Click here 

      Gems are chosen by the Goodfellow director Dr. Bruce Arroll to be either practice changing or practice maintaining. The information is educational and not clinical advice.

      Additional Resources

      You may also be interested in:
      As published in NZ Doctor 5/7/2017